Bolt Biotherapeutics (NASDAQ:BOLT) Receives “Buy” Rating from HC Wainwright

Bolt Biotherapeutics (NASDAQ:BOLT)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 66.47% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the company. Zacks Research cut Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $34.00.

Bolt Biotherapeutics Stock Up 3.8%

BOLT traded up $0.16 on Friday, hitting $4.21. The company had a trading volume of 3,736 shares, compared to its average volume of 26,231. The stock has a fifty day simple moving average of $5.44 and a 200-day simple moving average of $5.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57. The firm has a market capitalization of $8.07 million, a P/E ratio of -0.19 and a beta of 0.94. Bolt Biotherapeutics has a 52-week low of $4.01 and a 52-week high of $9.66.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Thursday, March 12th. The company reported ($3.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.27) by $0.43. The firm had revenue of $2.50 million for the quarter. As a group, equities analysts expect that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

A number of hedge funds have recently made changes to their positions in BOLT. Squarepoint Ops LLC grew its stake in shares of Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares during the last quarter. Shay Capital LLC bought a new position in Bolt Biotherapeutics during the 3rd quarter valued at approximately $85,000. Susquehanna International Group LLP purchased a new position in Bolt Biotherapeutics during the third quarter valued at $89,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Bolt Biotherapeutics during the fourth quarter valued at $112,000. Finally, T3 Companies LLC bought a new stake in Bolt Biotherapeutics in the fourth quarter worth $208,000. 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.